GlassScriptPhysician profile
Gregory J Branche
NPI 1598731135
$7,926.04
in general payments reported to CMS, 2019-2025
18 companies · $2,503 in 2025
The $2,503 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $563 · 2023: $1,608 · 2024: $2,365 · 2025: $2,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,337 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,337.40 |
| Education | $138.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,689.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $784.32 | 2021-2025 | |
| Ucb, INC. | $696.04 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $679.69 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $617.68 | 2021-2025 | Tremfya |
| Amgen INC. | $492.14 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $444.28 | 2021-2025 | |
| Dermavant Sciences, INC. | $418.58 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $415.53 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $360.91 | 2023-2025 | Ilumya |
| Pfizer INC. | $359.73 | 2021-2025 | |
| Lilly USA, LLC | $294.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $292.96 | 2023-2024 | Opzelura |
| Penumbra, INC. | $169.44 | 2024 | Penumbra System |
| Galderma Laboratories, L.P. | $105.56 | 2021-2025 | Nemluvio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $48.02 | 2022-2023 | Dupixent |
| Organon LLC | $36.69 | 2025 | Vtama |
| Leo Pharma INC. | $20.32 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Branche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.